Jefferies Financial Group Inc. Purchases New Shares in Replimune Group, Inc. $REPL

Jefferies Financial Group Inc. purchased a new position in Replimune Group, Inc. (NASDAQ:REPL) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 495,465 shares of the company’s stock, valued at approximately $5,485,000.

A number of other institutional investors have also added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Replimune Group by 17.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock valued at $435,000 after buying an additional 6,653 shares in the last quarter. Millennium Management LLC grew its position in shares of Replimune Group by 2.8% in the 1st quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock worth $11,927,000 after buying an additional 33,574 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Replimune Group by 20.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock worth $6,729,000 after acquiring an additional 119,145 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Replimune Group by 6.9% in the 2nd quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock worth $948,000 after acquiring an additional 6,616 shares in the last quarter. Finally, Sei Investments Co. lifted its position in Replimune Group by 149.5% during the 2nd quarter. Sei Investments Co. now owns 30,478 shares of the company’s stock valued at $283,000 after acquiring an additional 18,263 shares during the period. Institutional investors own 92.53% of the company’s stock.

Replimune Group Stock Down 0.6%

REPL opened at $15.50 on Friday. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of -4.92 and a beta of 0.88. The firm has a 50 day moving average price of $11.84 and a 200-day moving average price of $8.34. Replimune Group, Inc. has a twelve month low of $1.50 and a twelve month high of $16.15. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 1.00.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). Equities research analysts forecast that Replimune Group, Inc. will post -2.94 earnings per share for the current year.

Analyst Upgrades and Downgrades

REPL has been the topic of a number of recent research reports. Wolfe Research upgraded shares of Replimune Group to an “outperform” rating in a report on Tuesday, August 4th. JPMorgan Chase & Co. boosted their price target on Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday. Piper Sandler raised Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective on the stock in a research report on Friday, August 7th. Finally, Wall Street Zen upgraded Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $12.00.

Insider Buying and Selling at Replimune Group

In other news, CFO Emily Luisa Hill sold 9,256 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $14.28, for a total transaction of $132,175.68. Following the completion of the sale, the chief financial officer owned 215,852 shares of the company’s stock, valued at $3,082,366.56. The trade was a 4.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sushil Patel sold 39,341 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $510,252.77. Following the completion of the sale, the chief executive officer owned 708,151 shares of the company’s stock, valued at $9,184,718.47. This trade represents a 5.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 91,124 shares of company stock valued at $1,149,244 in the last quarter. Insiders own 5.40% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.